A trial of RIT-4237 rotavirus vaccine in 1-month-old infants.
In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month follow-up period. During a 6 month follow-up, stool samples from 2 out of 12 vaccinees and from 5 out of 12 placebo recipients contained rotavirus.
Mutz
I D
ID
Kinderabteilung, Landeskrankenhaus Leoben, Austria.
Krainer
F
F
Deutsch
J
J
Kunz
C
C
Teuwen
D E
DE
D000917:Antibody Formation; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005759:Gastroenteritis / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D007223:Infant; D007231:Infant, Newborn; D010919:Placebos; D011897:Random Allocation; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control*; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use*
D007075:Immunoglobulin M; D010919:Placebos; C041165:RIT 4237 vaccine; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated; D014765:Viral Vaccines